|
| Sat, 6 May 2006 18:00:00 EST What it will take to win the war on terrorism |
| The movie "United 93" comes at an opportune moment in this fifth year of the war on terrorism. Those who see the movie cannot fail to be deeply moved by the intelligence, initiative, and courage of the ordinary-extraordinary Americans on board. They came face to face with Islamofascism, recognized it for the unalloyed evil it is, and died thwarting its likely mission, to destroy the White House. |
| Sat, 6 May 2006 18:00:00 EST Talk plus meds to beat booze; take more steps with your kids; going the full round with chemo; what if the nation gets the flu? |
| 'I've lost the craving to drink," marvels Walter Kent. The 61-year-old from Cumberland, R.I., is one of nearly 1,400 alcoholics who participated in a stop-drinking study reported in the Journal of the American Medical Association. Prior to the study, they had been guzzling booze, on average, 3 days out of every 4. Over four months, researchers put them on various combinations of medication and counseling. The best results came from naltrexone, a pill that dulls the urge to drink, and nine short sessions in which doctors, nurses, and pharmacists talked with them about ways to stay with treatment. "At the end, people were drinking only 1 day in every 5," says Robert Swift, a Brown Medical School psychiatrist who was one of the investigators; 20 to 30 percent were completely dry. That's good. And it shows that people might be able to get help from ordinary doctors, not just from special rehab services. |
| Sat, 6 May 2006 18:00:00 EST On the record: Robert Bruner |
| With Enron's top executives, Kenneth Lay and Jeffrey Skilling, on trial for conspiracy and fraud--and a third, Andrew Fastow, testifying against them--the nightmare of the biggest bankruptcy in history is back. So are the questions that have dogged business experts since Enron's collapse: What really happened at the energy giant--and what can be learned from its demise? In a popular case study of the company, Robert Bruner, dean of the Darden Graduate School of Business Administration at the University of Virginia, and his coauthor, Samuel Bodily, a professor of business administration, have tried to provide a few answers--arguing, surprisingly, for a longer view of Enron's rise and fall. Bruner spoke with Senior Editor Justin Ewers: |
powered by zFeeder and Browse8.com |